The National Institutes of Health is considering granting a worldwide exclusive evaluation option license to Andover, Mass.-based Mehr Medical for a caval-aortic device for aortic valve replacement, a Thursday Federal Register notice says.
The license would grant Mehr Medical the right to make and use — but not sell — the NIH’s implant technology for closing a caval-aortic iatrogenic fistula created when a transcatheter device is introduced from the inferior vena cava to the abdominal aorta. The device “includes an expandable transvascular implant with an elastomeric surface capable of extending between a vein and artery which conforms to the boundaries of an arteriovenous fistula tract between the artery and vein,” the notice says.
Following the expiration of the evaluation license, Mehr may apply for a start-up exclusive patent commercialization license.
Read the Federal Register notice at www.fdanews.com/ext/resources/files/03/03-07-14-License.pdf. — Lena Freund
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.